Selected article for: "antiviral therapeutic and Ebola virus"
Author: Laura Riva; Shuofeng Yuan; Xin Yin; Laura Martin-Sancho; Naoko Matsunaga; Sebastian Burgstaller-Muehlbacher; Lars Pache; Paul P. De Jesus; Mitchell V. Hull; Max Chang; Jasper Fuk-Woo Chan; Jianli Cao; Vincent Kwok-Man Poon; Kristina Herbert; Tu-Trinh Nguyen; Yuan Pu; Courtney Nguyen; Andrey Rubanov; Luis Martinez-Sobrido; Wen-Chun Liu; Lisa Miorin; Kris M. White; Jeffrey R. Johnson; Christopher Benner; Ren Sun; Peter G. Schultz; Andrew Su; Adolfo Garcia-Sastre; Arnab K. Chatterjee; Kwok-Yung Yuen; Sumit K. Chanda
Title: A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals
  • Document date: 2020_4_17
    • ID: 1fgnfh62_4
    Snippet: The repurposing of several approved antiviral therapies have all been the focus of clinical investigations, including HIV-1 protease inhibitors lopinavir/ritonavir (Kaletra, Aluvia by AbbVie) 19 , hepatitis C virus protease inhibitor danoprevir (Ganovo, Ascletis Pharma) 20 , and the influenza antiviral favipiravir (T-705, Avigan) 21 . Most notably, ten clinical trials at more than 50 global sites are underway to investigate remdesivir (GS-5734), .....
    Document: The repurposing of several approved antiviral therapies have all been the focus of clinical investigations, including HIV-1 protease inhibitors lopinavir/ritonavir (Kaletra, Aluvia by AbbVie) 19 , hepatitis C virus protease inhibitor danoprevir (Ganovo, Ascletis Pharma) 20 , and the influenza antiviral favipiravir (T-705, Avigan) 21 . Most notably, ten clinical trials at more than 50 global sites are underway to investigate remdesivir (GS-5734), an investigational antiviral originally developed by Gilead Sciences to treat Ebola virus infection 22 . Remdesivir, an adenosine analogue, is a viral RNA polymerase inhibitor that causes premature termination of transcription when incorporated into nascent viral RNA 23 . The drug has demonstrated in vitro and in vivo activity in animal models against both MERS and SARS 24, 25 , as well as potent antiviral activity in Vero E6 against a clinical isolate of SARS-CoV-2 26 . Pending results of several randomized (n = 308) clinical trials are expected to provide definitive insight into the efficacy of remdesivir as a therapeutic solution for the treatment of COVID-19. However, a wellpowered randomized controlled trial has yet to demonstrate definitive evidence of antiviral efficacy for remdesivir or any other potential therapeutic.

    Search related documents:
    Co phrase search for related documents
    • adenosine analogue and antiviral efficacy: 1, 2, 3
    • adenosine analogue and Ebola virus: 1, 2, 3, 4
    • adenosine analogue and Ebola virus infection: 1, 2
    • animal model and antiviral activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • animal model and antiviral efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • animal model and antiviral therapy: 1, 2, 3, 4
    • animal model and clinical investigation: 1, 2
    • animal model and clinical isolate: 1, 2
    • animal model and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • animal model and control trial: 1, 2, 3, 4
    • animal model and definitive evidence: 1, 2, 3
    • animal model and Ebola virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • antiviral activity and clinical investigation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • antiviral activity and clinical isolate: 1, 2, 3, 4, 5, 6, 7, 8
    • antiviral activity and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral activity and control trial: 1, 2
    • antiviral activity and definitive evidence: 1, 2, 3, 4, 5
    • antiviral activity and Ebola virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral activity and investigational antiviral: 1, 2, 3, 4, 5